TKI/Immunotherapy Combos Lead Advances in mRCC, But Questions Remain
Published: Wednesday, Mar 11, 2020
Chung-Han Lee, MD, PhD
Three immunotherapy combinations have transformed first-line treatment for patients with metastatic renal cell carcinoma (mRCC), yet questions remain on what the optimal strategy is for patients who progress on these regimens, explained Chung-Han (Joe) Lee, MD, PhD.
... to read the full story